{"success":true,"data":{"pressRelease":{"id":"114638","rtpr_id":"nBw6nZkq7a","ticker":"DMAC","exchange":"NASDAQ","all_tickers":["DMAC"],"title":"DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights","author":"Business Wire","published_at":"2026-08-10T20:30:00.379Z","article_body":"DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and\nProvides Business Highlights\n\n\n * Enrollment Complete in First Cohort of Phase 2 Early-Onset Fetal Growth\nRestriction Trial; Key Opinion Leader Call and Topline Results to Be Held in\nSeptember\n\n * Positive Topline Results from Phase 2 Late-Onset Preeclampsia Part 1a\nDose-Extension Cohort, Demonstrating Rapid, Clinically Meaningful, and\nStatistically Significant Reductions in Maternal Blood Pressure\n\n * Enrollment for Acute Ischemic Stroke Phase 2/3 Trial Progressing with Interim\nAnalysis Anticipated Q1 2027\n\n * $43.5 million in Cash, Cash Equivalents and Investments, Anticipated Runway\nthrough 2027\n\n * Conference Call and Webcast August 11 at 8:00 AM Eastern Time / 7:00 AM\nCentral Time\n\nDiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical\ncompany focused on developing novel treatments for preeclampsia, fetal growth\nrestriction and acute ischemic stroke, today provided a business update and\nreported financial results for the second quarter ended June 30, 2026.\nManagement will host a conference call Tuesday, August 11, 2026, at 8:00 AM\nEastern Time / 7:00 AM Central Time to discuss its business update and second\nquarter 2026 financial results.\n\n“With the recent positive interim results from Part 1a of our Phase 2 study\nevaluating DM199 in preeclampsia, we’re eager to continue advancement of\nthis promising candidate to address ischemic diseases in the second half of\nthis year,” said Rick Pauls, President and CEO of DiaMedica.\n“Preeclampsia, fetal growth restriction and stroke are areas with high unmet\nmedical need due to the lack of approved treatment options, and we believe\nDM199 has the potential to provide a disease-modifying solution for patients\nsuffering from these ischemic conditions. We look forward to sharing results\nof the recently completed first cohort of fetal growth restriction and\ninitiating subsequent studies in the ongoing investigator-sponsored Phase 2,\nopen label trial in these indications.”\n\n“In Part 1a of the Phase 2 study evaluating DM199 in women with preeclampsia\nwith expected delivery within 72 hours, the most clinically meaningful\npharmacodynamic effects were observed in the mid-dose range, Cohorts 4 through\n8, where patients showed reductions in both maternal blood pressure and\nuterine artery pulsatility index (PI). Reductions in PI are consistent with\nreduced uteroplacental vascular resistance, improved blood flow and the\npotential to modify the underlying disease process in these patient\npopulations,” said Julie Krop, MD, Chief Medical Officer of DiaMedica.\n“These findings represent significant progress for our preeclampsia program\nas they support selection of the mid-dose range for further clinical\nevaluation in our early-onset preeclampsia and fetal growth restriction\nstudies.”\n\nRecent Corporate Highlights\n\n\n * Fetal Growth Restriction (FGR) Phase 2 Update: Enrollment of the first of\nthree planned cohorts has been completed, consisting of 6 participants at the\n5 µg/kg dose level. This is the first time DM199 has been used to treat\nearly-onset fetal growth restriction patients. A key opinion leader (KOL) call\nis being scheduled in September, with leading preeclampsia OBGYN and study\nPrincipal Investigator Dr. Cathy Cluver, to discuss the clinical case for\nDM199’s therapeutic potential in FGR and top line results from the first\ncohort.\n\n * Preeclampsia (PE) Phase 2 Part 1a Topline Results: DM199 produced clinically\nmeaningful and statistically significant, sustained reductions in maternal\nblood pressure in late-onset PE. In the combined final, highest-dose cohorts\n(n=15; cohort 10 and extension cohort), DM199 produced a mean 29.1 mmHg\nreduction in systolic blood pressure (SBP) from a baseline mean of 169.3 mmHg\n(p<0.001) and a 17.0 mmHg reduction in diastolic blood pressure (DBP) from\na baseline mean of 103.7 mmHg (p<0.001) at the pre-specified time point of\nfive minutes after completion of the IV infusion. SBP was maintained below 160\nmmHg at all measured time points over 24 hours (p<0.01). The combined\ncohort consisted of 15 PE subjects, three from the initial dose escalation\nphase and 12 additional subjects enrolled in the extension cohort.\n\n\n\nDetailed Part 1a results, including pharmacokinetic and pharmacodynamic\nanalyses, are expected to be presented at an upcoming medical conference and\nsubmitted for publication.\n\n\n\nDiaMedica is also preparing to initiate a concurrent open-label three dose\nPhase 2 study in early-onset preeclampsia in North America and the United\nKingdom to further support Phase 3 dose selection.\n\n\n * Acute Ischemic Stroke (AIS) ReMEDy2 Phase 2/3 Clinical Developments:\nEnrollment in the Company’s Phase 2/3 ReMEDy2 (the ReMEDy2 trial –\nNCT05065216) trial has surpassed 85% of the 200 participants required to\ntrigger the prespecified interim analysis. The Company now has approximately\n70 activated sites across the United States, Canada, the United Kingdom, and\nsix European countries added earlier this year, and expects the interim\nanalysis to read out in early 2027.\n\n * Health Canada Authorizes Global Phase 2 Early-Onset Preeclampsia Study: Health\nCanada authorized initiation of the Company’s open-label, sequential-cohort\nPhase 2 dose-finding study in early-onset preeclampsia, designed to enroll\napproximately 30 PE patients across three dose levels informed by the Part 1a\nresults. DiaMedica is working with sites in Canada and expects to dose its\nfirst patient in the fourth quarter of 2026, and is also preparing to expand\nthe study to the United Kingdom later this year, subject to regulatory\nauthorization and site readiness.\n\n * U.S. Regulatory Update on IND Pathway: In June 2026, DiaMedica received\nwritten feedback from the FDA regarding the nonclinical reproductive toxicity\ninformation needed to support a U.S. IND application for DM199 in\npreeclampsia. Based on this feedback, the Company believes that the previously\ncompleted rat reproductive toxicity study may be adequate to support IND\nclearance, provided DiaMedica can demonstrate adequate DM199 exposure,\nenzymatic activity, and pharmacologic effect in rats. DiaMedica has initiated\na rat pharmacokinetic and pharmacologic activity study and, once complete,\nplans to submit the data package to FDA for review.\n\nFinancial Results Highlights for the Quarter Ended June 30, 2026\n\n\n * Cash Position and Runway – Cash, cash equivalents and short-term investments\nwere $43.5 million as of June 30, 2026, compared to $59.9 million as of\nDecember 31, 2025. Current liabilities were $6.6 million as of June 30, 2026,\nresulting in working capital of $37.7 million, compared to current liabilities\nof $5.1 million and working capital of $55.5 million as of December 31, 2025.\nBased on its current plans, the Company anticipates its current cash, cash\nequivalents and short-term investments will enable the Company to fund its\nplanned clinical studies and support corporate operations through 2027.\n\n * Cash Flows – Net cash used in operating activities for the six months ended\nJune 30, 2026 was $17.2 million compared to $14.7 million for the same period\nin 2025. The increase resulted primarily from the increased net loss,\npartially offset by changes in operating assets and liabilities during the\ncurrent year period.\n\n * Research and Development (R&D) – R&D expenses were $8.2 million and\n$16.1 million for the three and six months ended June 30, 2026, respectively,\nup from $5.8 million and $11.5 million for the three and six months ended June\n30, 2025, respectively. The increases were due primarily to the expansion of\nthe Company’s clinical team, its ongoing ReMEDy2 clinical trial, including\nits global expansion, costs related to additional reproductive toxicity\ntesting performed in support of the Company’s preeclampsia program in the\nUnited States, increased manufacturing development activity, and increased\nnon-cash share-based compensation. The Company expects R&D expenses to\nincrease moderately in future periods relative to recent prior periods as it\ncontinues the ReMEDy2 trial, including its global expansion, and continues to\nexpand its DM199 clinical development program into preeclampsia.\n\n * General and Administrative (G&A) – G&A expenses were $2.3 million\nand $4.8 million for the three and six months ended June 30, 2026,\nrespectively, up slightly from $2.2 million and $4.7 million for the three and\nsix months ended June 30, 2025, respectively. The increase for the three-month\nperiod was driven primarily by increased non-cash share-based compensation and\nprofessional fees, while the increase for the six-month period resulted\nprimarily from increased personnel costs incurred in conjunction with\nexpanding our team, partially offset by a reduction in current-year legal and\nother professional fees. The Company expects G&A expenses to remain\nrelatively steady in future periods compared to recent prior periods.\n\n * Net Loss – Net losses were $10.1 million and $20.2 million for the three and\nsix months ended June 30, 2026, respectively, up from $7.7 million and $15.4\nmillion for the three and six months ended June 30, 2025, respectively.\n\nConference Call and Webcast Information\n\nDiaMedica Management will host a conference call and webcast to discuss its\nbusiness update and second quarter 2026 financial results on Tuesday, August\n11, 2026, at 8:00 AM Eastern Time / 7:00 AM Central Time:\n Date:       Tuesday, August 11, 2026 \n Time:       8:00 AM EDT / 7:00 AM CDT \n Web access:       https://app.webinar.net/d01wEPk9peA \n (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fus-west \n -2.protection.sophos.com%3Fd%3Dwebinar.net%26u%3DaHR0cHM6Ly9hcHAud2ViaW5hci5uZXQvZDAxd0VQazlwZUE%3D%26 \n i%3DNjU1NmE0NWY4MzA0ZjA2ZTMwNTBjNWRl%26t%3DSlZVdTZFS2dNVHZob3EzVWw5T3labVo5T0lRMjA0STJJRitjZHhRUUl6VT0 \n %3D%26h%3Dd8712cf45d40436683cd7f24bfd08df0%26s%3DAVNPUEhUT0NFTkNSWVBUSVagcGhTvF8 \n -Bs7rQnZnEvkEJGgc_FRdVzAi4rYqRtUJCps5v1Yh3p7o0E9-H4WEXtkE1ZrBEb6KhPp \n -jKfxjUcw&esheet=54586996&newsitemid=20260810989621&lan=en \n -US&anchor=https%3A%2F%2Fapp.webinar.net%2Fd01wEPk9peA&index=1&md5=c1a542752244787d6e9d815 \n d59c049f4) \n Dial In:       (646) 357-8766 \n Conference ID:       2224408 \n\n\nInterested parties may access the conference call by dialing in or listening\nto the simultaneous webcast. Listeners should log on to the website or dial in\n15 minutes prior to the call. The webcast will remain available for play back\non the Company’s website, under investor relations - events and\npresentations\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.diamedica.com%2Finvestors%2Fevents-presentations&esheet=54586996&newsitemid=20260810989621&lan=en-US&anchor=investor+relations+-+events+and+presentations&index=2&md5=e873a6762d1db741d99756c164348623)\n, following the earnings call and for 12 months thereafter. A telephonic\nreplay of the conference call will be available until August 18, 2026, by\ndialing (880) 770-2030 (US Toll Free) and entering the replay passcode:\n2224408#.\n\nAbout the Phase 2 IST of DM199 in Preeclampsia and Fetal Growth Restriction\n\nThe Phase 2 study is an open-label, single center, single-arm, safety and\npharmacodynamic, proof-of-concept, investigator-sponsored trial of DM199 for\nthe treatment of PE is currently being conducted at the Tygerberg Hospital in\nCape Town, South Africa. This Phase 2 study consists of three studies (Part\n1a, Part 1b and Part 2) in PE and a single study in FGR. Part 1a has been\ncompleted; the FGR study has initiated enrollment, and its first cohort of 6\nparticipants has been enrolled; and Parts 1b and 2 are expected to initiate in\nSeptember or October of 2026, as follows:\"\n\nPreeclampsia (PE)\n\n\n * Part 1a late-onset PE: dose-escalation study evaluating single intravenous\n(IV) / single subcutaneous (SC) DM199 doses in late-onset PE subjects enrolled\nwithin 72 hours of delivery, including a confirmatory extension cohort of up\nto 12 participants at the cohort 10 dose level, which was completed in June\n2026.\n\n * Part 1b late-onset PE: dose-expansion study evaluating continuous IV infusion\nin up to 30 late-onset PE subjects enrolled within 72 hours of delivery, using\na dosing level identified in Part 1a; initial enrollment expected in September\nor October 2026.\n\n * Part 2 early-onset PE: evaluation of repeated SC dosing of DM199 in up to 30\nearly-onset PE subjects until delivery (expectant management), using three\ndose levels at 5, 10 and up to 15 µg/kg. The dose for the third cohort will\nbe between 1 and 15 µg/kg based on results from the first two cohorts;\ninitial enrollment expected in September or October 2026.\n\nFetal Growth Restriction (FGR)\n\n\n * Part 3 early-onset FGR: evaluating repeated SC dosing in up to 30 early-onset\nFGR subjects until delivery, using up to three dose levels initially based on\nPart 1a data; enrollment commenced in June 2026 and the first cohort of 6\nparticipants has been enrolled. Dosing levels are at 5, 10 and up to 15\nµg/kg. The dose for the third cohort will be between 1 and 15 µg/kg based on\nresults from the first two cohorts.\n\nAbout Fetal Growth Restriction\n\nFetal growth restriction (FGR) occurs when a fetus fails to reach its\ngenetically determined growth potential in the womb, most commonly due to\nplacental insufficiency. FGR affects an estimated 10% of pregnancies worldwide\nand is associated with significantly increased risks of stillbirth, preterm\nbirth, and neonatal morbidity, as well as long-term neurodevelopmental,\ncardiovascular, and metabolic complications. In severe, early-onset cases, FGR\noften necessitates delivery before 32 weeks of gestation, when the risks of\nprematurity must be weighed against the dangers of continued growth\nrestriction in utero. See the recently released white paper, “The Potential\nof DM199 to Treat Fetal Growth Restriction\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fd1io3yog0oux5.cloudfront.net%2F_de2d89f8a81650134a07cdc600a9236c%2Fdiamedica%2Fdb%2F202%2F3331%2Fpdf%2FTHE%2BPOTENTIAL%2BOF%2BDM199%2BTO%2BTREAT%2BFETAL%2BGROWTH%2BRESTRICTION.pdf&esheet=54586996&newsitemid=20260810989621&lan=en-US&anchor=The+Potential+of+DM199+to+Treat+Fetal+Growth+Restriction&index=3&md5=dbdaddeeb72ffbeebfbd06ff48056bab)\n.”\n\nAbout Preeclampsia\n\nPreeclampsia is a serious pregnancy disorder that typically develops after the\n20th week of gestation, characterized by high blood pressure and damage to\norgan systems, often the kidneys and liver. Affecting up to 8% of pregnancies\nworldwide, preeclampsia can pose significant risks to both the mother and\nbaby, including risk of stroke, placental abruption, progression to eclampsia,\npremature delivery, and death. Preeclampsia occurs in two stages. First, in\nearly pregnancy, the placenta fails to embed properly in the wall of the\nuterus, and the spiral arteries in the uterine wall that are supposed to\ndilate to promote healthy blood flow to the placenta do not widen. Stage 2\nthen occurs after 20 weeks of pregnancy as the placenta, which has been\nchronically starved of oxygen from the blood, begins to release noxious\nfactors into the mother’s circulation, inflicting widespread damage to her\nblood vessels and causing systemic endothelial dysfunction. Symptoms may\ninclude severe headaches, vision changes, upper abdominal pain and swelling in\nthe hands and face. Delivery of the baby, often very prematurely, is the only\navailable option for stopping the progression of preeclampsia. Women who have\nhad preeclampsia have three to four times the risk of high blood pressure and\ndouble the risk for heart disease and stroke.\n\nAbout Acute Ischemic Stroke\n\nAcute ischemic stroke (AIS) occurs when a blood clot blocks a vessel supplying\nblood to the brain, leading to a sudden loss of oxygen and nutrients and, if\nnot corrected, ultimately neuronal cell death. According to the U.S. Center\nfor Disease Control, stroke causes approximately one out of every 20 deaths in\nthe U.S. each year, and nearly nine out of 10 strokes are ischemic. No new\ntherapeutics have been approved for acute ischemic stroke in over 25 years.\nWhen a blood vessel in the brain becomes blocked during a stroke, a core area\nof the affected brain tissue will typically suffer a nearly complete loss of\nblood flow, while the surrounding area (the “ischemic penumbra”) receives\nonly about 20-40% of normal blood flow. Cells in the core area are rapidly\ndepleted of their oxygen and glucose stores, leading, often within minutes, to\ncell death. The cells in the penumbral area may remain viable for several\nhours but are eventually at risk of damage.\n\nAbout DiaMedica Therapeutics Inc.\n\nDiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company\ncommitted to improving the lives of people suffering from serious ischemic\ndiseases with a focus on preeclampsia, fetal growth restriction and acute\nischemic stroke. DiaMedica’s lead candidate DM199 is the first\npharmaceutically active recombinant (synthetic) form of the KLK1 protein, an\nestablished therapeutic modality in Asia for the treatment of acute ischemic\nstroke, preeclampsia and other vascular diseases. For more information visit\nthe Company’s website at www.diamedica.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.diamedica.com&esheet=54586996&newsitemid=20260810989621&lan=en-US&anchor=www.diamedica.com&index=4&md5=9b4b94de2913a03d49b3dc95ae3ac67e)\n.\n\nCautionary Note Regarding Forward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nthe U.S. Private Securities Litigation Reform Act of 1995 and forward-looking\ninformation that are based on the beliefs of management and reflect\nmanagement’s current expectations. When used in this press release, the\nwords “anticipate,” “believe,” “continue,” “could,”\n“estimate,” “expect,” “intend,” “may,” “might,”\n“plan,” “potential,” “predict,” “project,” “seek,”\n“should,” “target,” “will,” or “would,” the negative of these\nwords or such variations thereon or comparable terminology and the use of\nfuture dates are intended to identify forward-looking statements and\ninformation. The forward-looking statements and information in this press\nrelease include statements regarding the timing, nature and requirements for\nregulatory applications and approvals, including its application for an IND\nfor the study of DM199 as a treatment for preeclampsia and fetal growth\nrestriction and its conducting a Phase 2 trial in these indications; continued\nReMEDy2 trial enrollment and timing of the interim analysis; anticipated\nclinical benefits and success of DM199 for the treatment of preeclampsia,\nfetal growth restriction and acute ischemic stroke; future R&D and G&A\nexpenses and the Company’s projected cash runway. By their nature,\nforward-looking statements involve known and unknown risks, uncertainties and\nother factors which may cause actual results, performance or achievements, or\nother future events, to be materially different from any future results,\nperformance or achievements expressed or implied by such forward-looking\nstatements. Applicable risks and uncertainties include, among others, risks\nand uncertainties relating to the timing and outcomes of non-clinical studies;\nrisks and uncertainties relating to the timing of studies and trials; risks\nand uncertainties relating to the clinical expansion into preeclampsia and\nassociated trials; the risk that existing preclinical and clinical data may\nnot be predictive of the results of ongoing or later clinical trials;\nDiaMedica’s plans to develop, obtain regulatory approval for and\ncommercialize its DM199 product candidate for the treatment of preeclampsia,\nfetal growth restriction, and acute ischemic stroke and its expectations\nregarding the benefits of DM199; DiaMedica’s ability to conduct successful\nclinical testing of DM199 and within its anticipated parameters, site\nactivations, enrollment numbers, costs and timeframes; the perceived benefits\nof DM199 over existing treatment options; the potential direct or indirect\nimpact of hospital and medical facility staffing shortages, increased tariffs\nand worldwide global supply chain shortages on DiaMedica’s business and\nclinical trials, including its ability to meet its site activation and\nenrollment goals; DiaMedica’s reliance on collaboration with third parties\nto conduct clinical trials; DiaMedica’s ability to continue to obtain\nfunding for its operations, including funding necessary to complete current\nand planned clinical trials and obtain regulatory approvals for DM199 for\npreeclampsia, fetal growth restriction, and acute ischemic stroke; and the\nrisks identified under the heading “Risk Factors” in DiaMedica’s annual\nreport on Form 10-K for the fiscal year ended December 31, 2025 filed with the\nU.S. Securities and Exchange Commission (SEC) and subsequent SEC reports,\nincluding our most recent quarterly report on Form 10-Q. The forward-looking\ninformation contained in this press release represents the expectations of\nDiaMedica as of the date of this press release and, accordingly, is subject to\nchange after such date. Readers should not place undue importance on\nforward-looking information and should not rely upon this information as of\nany other date. While DiaMedica may elect to, it does not undertake to update\nthis information at any particular time except as required in accordance with\napplicable laws.\n   \n   \n   \n DiaMedica Therapeutics Inc. \n \nCondensed Consolidated Statements of Operations and Comprehensive Loss \n \n(In thousands, except share and per share amounts) \n \n(Unaudited)  \n   \n   Three Months Ended June 30,     Six Months Ended June 30,   \n   2026     2025     2026     2025   \n Operating expenses:                               \n Research and development $ 8,153     $ 5,822     $ 16,140     $ 11,478   \n General and administrative   2,345       2,185       4,840       4,673   \n Operating loss   (10,498 )     (8,007 )     (20,980 )     (16,151 ) \n                                 \n Other income, net   366       314       813       757   \n                                 \n Loss before income tax expense   (10,132 )     (7,693 )     (20,167 )     (15,394 ) \n                                 \n Income tax expense   (7 )     (6 )     (14 )     (12 ) \n                                 \n Net loss   (10,139 )     (7,699 )     (20,181 )     (15,406 ) \n                                 \n Other comprehensive loss                               \n Unrealized loss on marketable securities   (11 )     (19 )     (87 )     (37 ) \n                                 \n Net loss and comprehensive loss $ (10,150 )   $ (7,718 )   $ (20,268 )   $ (15,443 ) \n                                 \n Basic and diluted net loss per share $ (0.19 )   $ (0.18 )   $ (0.38 )   $ (0.36 ) \n Weighted average shares outstanding – basic and diluted   53,894,295       42,957,619       53,844,171       42,901,093   \n\n   \n   \n   \n   \n DiaMedica Therapeutics Inc. \n \nCondensed Consolidated Balance Sheets \n \n(In thousands, except share amounts)  \n   \n     June 30, 2026     December 31, 2025   \n     (unaudited)           \n ASSETS                 \n Current assets:                 \n Cash and cash equivalents   $ 5,129     $ 15,647   \n Marketable securities     38,375       44,243   \n Prepaid expenses and other assets     567       481   \n Amounts receivable     244       258   \n Total current assets     44,315       60,629   \n                   \n Non-current assets:                 \n Operating lease right-of-use asset, net     400       400   \n Property and equipment, net     153       197   \n Deposits     133       145   \n Total non-current assets     686       742   \n                   \n Total assets   $ 45,001     $ 61,371   \n                   \n LIABILITIES AND EQUITY                 \n Current liabilities:                 \n Accounts payable   $ 2,812     $ 1,475   \n Accrued liabilities     3,666       3,545   \n Operating lease obligation     107       101   \n Finance lease obligation     9       11   \n Total current liabilities     6,594       5,132   \n                   \n Non-current liabilities:                 \n Operating lease obligation     69       124   \n Finance lease obligation     —       4   \n Total non-current liabilities     69       128   \n                   \n Shareholders’ equity:                 \n Common shares, no par value; unlimited authorized; 53,925,697 and 42,818,660     —       —   \n shares issued and outstanding, as of June 30, 2026 and December 31, 2025, \n respectively \n Paid-in capital     231,324       228,829   \n Accumulated other comprehensive income (loss)     (37 )     50   \n Accumulated deficit     (192,949 )     (172,768 ) \n Total shareholders’ equity     38,338       56,111   \n Total liabilities and shareholders’ equity   $ 45,001     $ 61,371   \n\n   \n   \n   \n   \n DiaMedica Therapeutics Inc. \n \nCondensed Consolidated Statements of Cash Flows \n \n(In thousands) \n \n(Unaudited)  \n   \n     Six Months Ended June 30,   \n     2026     2025   \n Cash flows from operating activities:                 \n Net loss   $ (20,181 )   $ (15,406 ) \n Adjustments to reconcile net loss to net cash used in operating activities:             \n Share-based compensation     1,940       1,638 \n Amortization of discounts on marketable securities     (359 )     (441 ) \n Non-cash lease expense     44       40   \n Depreciation     23       14   \n Changes in operating assets and liabilities:               \n Amounts receivable     14       75 \n Prepaid expenses and other assets     (86 )     (453 ) \n Deposits     —       1,108   \n Accounts payable     1,337       321   \n Accrued liabilities and operating lease liabilities     72       (1,643 ) \n Net cash used in operating activities     (17,196 )     (14,747 ) \n               \n Cash flows from investing activities:               \n Purchase of marketable securities     (23,650 )     (16,370 ) \n Maturities and sales of marketable securities     29,790       31,967 \n Purchases of property and equipment     (11 )     (18 ) \n Net cash provided by investing activities     6,129       15,579 \n               \n Cash flows from financing activities:               \n Proceed from the exercise of common stock options     555       257   \n Principal payments on finance lease obligation     (6 )     (5 ) \n Net cash provided by financing activities     549       252 \n             \n Net increase (decrease) in cash and cash equivalents     (10,518 )     1,084 \n Cash and cash equivalents at beginning of period     15,647       3,025 \n Cash and cash equivalents at end of period   $ 5,129     $ 4,109 \n                 \n Supplemental disclosure of non-cash transactions:                 \n Cash paid for income taxes   $ 13     $ 12 \n   \n   \n\n\n \n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260810989621/en/\n(https://www.businesswire.com/news/home/20260810989621/en/)\n\nScott Kellen\n\nChief Financial Officer\n\nPhone: (763) 496-5118\n\nskellen@diamedica.com (mailto:skellen@diamedica.com)\n\nFor Investor Inquiries: \n\nMike Moyer\n\nManaging Director, LifeSci Advisors, LLC\n\nPhone: (617) 308-4306\n\nmmoyer@lifesciadvisors.com (mailto:mmoyer@lifesciadvisors.com)\n\nMedia Contact: \n\nMadelin Hawtin\n\nLifeSci Communications\n\nmhawtin@lifescicomms.com \n(mailto:mhawtin@lifescicomms.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw6nZkq7a","title":"DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights","author":"Business Wire","ticker":"DMAC","created":"2026-08-10T20:30:00.379Z","tickers":["DMAC"],"exchange":"NASDAQ","article_body":"DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and\nProvides Business Highlights\n\n\n * Enrollment Complete in First Cohort of Phase 2 Early-Onset Fetal Growth\nRestriction Trial; Key Opinion Leader Call and Topline Results to Be Held in\nSeptember\n\n * Positive Topline Results from Phase 2 Late-Onset Preeclampsia Part 1a\nDose-Extension Cohort, Demonstrating Rapid, Clinically Meaningful, and\nStatistically Significant Reductions in Maternal Blood Pressure\n\n * Enrollment for Acute Ischemic Stroke Phase 2/3 Trial Progressing with Interim\nAnalysis Anticipated Q1 2027\n\n * $43.5 million in Cash, Cash Equivalents and Investments, Anticipated Runway\nthrough 2027\n\n * Conference Call and Webcast August 11 at 8:00 AM Eastern Time / 7:00 AM\nCentral Time\n\nDiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical\ncompany focused on developing novel treatments for preeclampsia, fetal growth\nrestriction and acute ischemic stroke, today provided a business update and\nreported financial results for the second quarter ended June 30, 2026.\nManagement will host a conference call Tuesday, August 11, 2026, at 8:00 AM\nEastern Time / 7:00 AM Central Time to discuss its business update and second\nquarter 2026 financial results.\n\n“With the recent positive interim results from Part 1a of our Phase 2 study\nevaluating DM199 in preeclampsia, we’re eager to continue advancement of\nthis promising candidate to address ischemic diseases in the second half of\nthis year,” said Rick Pauls, President and CEO of DiaMedica.\n“Preeclampsia, fetal growth restriction and stroke are areas with high unmet\nmedical need due to the lack of approved treatment options, and we believe\nDM199 has the potential to provide a disease-modifying solution for patients\nsuffering from these ischemic conditions. We look forward to sharing results\nof the recently completed first cohort of fetal growth restriction and\ninitiating subsequent studies in the ongoing investigator-sponsored Phase 2,\nopen label trial in these indications.”\n\n“In Part 1a of the Phase 2 study evaluating DM199 in women with preeclampsia\nwith expected delivery within 72 hours, the most clinically meaningful\npharmacodynamic effects were observed in the mid-dose range, Cohorts 4 through\n8, where patients showed reductions in both maternal blood pressure and\nuterine artery pulsatility index (PI). Reductions in PI are consistent with\nreduced uteroplacental vascular resistance, improved blood flow and the\npotential to modify the underlying disease process in these patient\npopulations,” said Julie Krop, MD, Chief Medical Officer of DiaMedica.\n“These findings represent significant progress for our preeclampsia program\nas they support selection of the mid-dose range for further clinical\nevaluation in our early-onset preeclampsia and fetal growth restriction\nstudies.”\n\nRecent Corporate Highlights\n\n\n * Fetal Growth Restriction (FGR) Phase 2 Update: Enrollment of the first of\nthree planned cohorts has been completed, consisting of 6 participants at the\n5 µg/kg dose level. This is the first time DM199 has been used to treat\nearly-onset fetal growth restriction patients. A key opinion leader (KOL) call\nis being scheduled in September, with leading preeclampsia OBGYN and study\nPrincipal Investigator Dr. Cathy Cluver, to discuss the clinical case for\nDM199’s therapeutic potential in FGR and top line results from the first\ncohort.\n\n * Preeclampsia (PE) Phase 2 Part 1a Topline Results: DM199 produced clinically\nmeaningful and statistically significant, sustained reductions in maternal\nblood pressure in late-onset PE. In the combined final, highest-dose cohorts\n(n=15; cohort 10 and extension cohort), DM199 produced a mean 29.1 mmHg\nreduction in systolic blood pressure (SBP) from a baseline mean of 169.3 mmHg\n(p<0.001) and a 17.0 mmHg reduction in diastolic blood pressure (DBP) from\na baseline mean of 103.7 mmHg (p<0.001) at the pre-specified time point of\nfive minutes after completion of the IV infusion. SBP was maintained below 160\nmmHg at all measured time points over 24 hours (p<0.01). The combined\ncohort consisted of 15 PE subjects, three from the initial dose escalation\nphase and 12 additional subjects enrolled in the extension cohort.\n\n\n\nDetailed Part 1a results, including pharmacokinetic and pharmacodynamic\nanalyses, are expected to be presented at an upcoming medical conference and\nsubmitted for publication.\n\n\n\nDiaMedica is also preparing to initiate a concurrent open-label three dose\nPhase 2 study in early-onset preeclampsia in North America and the United\nKingdom to further support Phase 3 dose selection.\n\n\n * Acute Ischemic Stroke (AIS) ReMEDy2 Phase 2/3 Clinical Developments:\nEnrollment in the Company’s Phase 2/3 ReMEDy2 (the ReMEDy2 trial –\nNCT05065216) trial has surpassed 85% of the 200 participants required to\ntrigger the prespecified interim analysis. The Company now has approximately\n70 activated sites across the United States, Canada, the United Kingdom, and\nsix European countries added earlier this year, and expects the interim\nanalysis to read out in early 2027.\n\n * Health Canada Authorizes Global Phase 2 Early-Onset Preeclampsia Study: Health\nCanada authorized initiation of the Company’s open-label, sequential-cohort\nPhase 2 dose-finding study in early-onset preeclampsia, designed to enroll\napproximately 30 PE patients across three dose levels informed by the Part 1a\nresults. DiaMedica is working with sites in Canada and expects to dose its\nfirst patient in the fourth quarter of 2026, and is also preparing to expand\nthe study to the United Kingdom later this year, subject to regulatory\nauthorization and site readiness.\n\n * U.S. Regulatory Update on IND Pathway: In June 2026, DiaMedica received\nwritten feedback from the FDA regarding the nonclinical reproductive toxicity\ninformation needed to support a U.S. IND application for DM199 in\npreeclampsia. Based on this feedback, the Company believes that the previously\ncompleted rat reproductive toxicity study may be adequate to support IND\nclearance, provided DiaMedica can demonstrate adequate DM199 exposure,\nenzymatic activity, and pharmacologic effect in rats. DiaMedica has initiated\na rat pharmacokinetic and pharmacologic activity study and, once complete,\nplans to submit the data package to FDA for review.\n\nFinancial Results Highlights for the Quarter Ended June 30, 2026\n\n\n * Cash Position and Runway – Cash, cash equivalents and short-term investments\nwere $43.5 million as of June 30, 2026, compared to $59.9 million as of\nDecember 31, 2025. Current liabilities were $6.6 million as of June 30, 2026,\nresulting in working capital of $37.7 million, compared to current liabilities\nof $5.1 million and working capital of $55.5 million as of December 31, 2025.\nBased on its current plans, the Company anticipates its current cash, cash\nequivalents and short-term investments will enable the Company to fund its\nplanned clinical studies and support corporate operations through 2027.\n\n * Cash Flows – Net cash used in operating activities for the six months ended\nJune 30, 2026 was $17.2 million compared to $14.7 million for the same period\nin 2025. The increase resulted primarily from the increased net loss,\npartially offset by changes in operating assets and liabilities during the\ncurrent year period.\n\n * Research and Development (R&D) – R&D expenses were $8.2 million and\n$16.1 million for the three and six months ended June 30, 2026, respectively,\nup from $5.8 million and $11.5 million for the three and six months ended June\n30, 2025, respectively. The increases were due primarily to the expansion of\nthe Company’s clinical team, its ongoing ReMEDy2 clinical trial, including\nits global expansion, costs related to additional reproductive toxicity\ntesting performed in support of the Company’s preeclampsia program in the\nUnited States, increased manufacturing development activity, and increased\nnon-cash share-based compensation. The Company expects R&D expenses to\nincrease moderately in future periods relative to recent prior periods as it\ncontinues the ReMEDy2 trial, including its global expansion, and continues to\nexpand its DM199 clinical development program into preeclampsia.\n\n * General and Administrative (G&A) – G&A expenses were $2.3 million\nand $4.8 million for the three and six months ended June 30, 2026,\nrespectively, up slightly from $2.2 million and $4.7 million for the three and\nsix months ended June 30, 2025, respectively. The increase for the three-month\nperiod was driven primarily by increased non-cash share-based compensation and\nprofessional fees, while the increase for the six-month period resulted\nprimarily from increased personnel costs incurred in conjunction with\nexpanding our team, partially offset by a reduction in current-year legal and\nother professional fees. The Company expects G&A expenses to remain\nrelatively steady in future periods compared to recent prior periods.\n\n * Net Loss – Net losses were $10.1 million and $20.2 million for the three and\nsix months ended June 30, 2026, respectively, up from $7.7 million and $15.4\nmillion for the three and six months ended June 30, 2025, respectively.\n\nConference Call and Webcast Information\n\nDiaMedica Management will host a conference call and webcast to discuss its\nbusiness update and second quarter 2026 financial results on Tuesday, August\n11, 2026, at 8:00 AM Eastern Time / 7:00 AM Central Time:\n Date:       Tuesday, August 11, 2026 \n Time:       8:00 AM EDT / 7:00 AM CDT \n Web access:       https://app.webinar.net/d01wEPk9peA \n (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fus-west \n -2.protection.sophos.com%3Fd%3Dwebinar.net%26u%3DaHR0cHM6Ly9hcHAud2ViaW5hci5uZXQvZDAxd0VQazlwZUE%3D%26 \n i%3DNjU1NmE0NWY4MzA0ZjA2ZTMwNTBjNWRl%26t%3DSlZVdTZFS2dNVHZob3EzVWw5T3labVo5T0lRMjA0STJJRitjZHhRUUl6VT0 \n %3D%26h%3Dd8712cf45d40436683cd7f24bfd08df0%26s%3DAVNPUEhUT0NFTkNSWVBUSVagcGhTvF8 \n -Bs7rQnZnEvkEJGgc_FRdVzAi4rYqRtUJCps5v1Yh3p7o0E9-H4WEXtkE1ZrBEb6KhPp \n -jKfxjUcw&esheet=54586996&newsitemid=20260810989621&lan=en \n -US&anchor=https%3A%2F%2Fapp.webinar.net%2Fd01wEPk9peA&index=1&md5=c1a542752244787d6e9d815 \n d59c049f4) \n Dial In:       (646) 357-8766 \n Conference ID:       2224408 \n\n\nInterested parties may access the conference call by dialing in or listening\nto the simultaneous webcast. Listeners should log on to the website or dial in\n15 minutes prior to the call. The webcast will remain available for play back\non the Company’s website, under investor relations - events and\npresentations\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.diamedica.com%2Finvestors%2Fevents-presentations&esheet=54586996&newsitemid=20260810989621&lan=en-US&anchor=investor+relations+-+events+and+presentations&index=2&md5=e873a6762d1db741d99756c164348623)\n, following the earnings call and for 12 months thereafter. A telephonic\nreplay of the conference call will be available until August 18, 2026, by\ndialing (880) 770-2030 (US Toll Free) and entering the replay passcode:\n2224408#.\n\nAbout the Phase 2 IST of DM199 in Preeclampsia and Fetal Growth Restriction\n\nThe Phase 2 study is an open-label, single center, single-arm, safety and\npharmacodynamic, proof-of-concept, investigator-sponsored trial of DM199 for\nthe treatment of PE is currently being conducted at the Tygerberg Hospital in\nCape Town, South Africa. This Phase 2 study consists of three studies (Part\n1a, Part 1b and Part 2) in PE and a single study in FGR. Part 1a has been\ncompleted; the FGR study has initiated enrollment, and its first cohort of 6\nparticipants has been enrolled; and Parts 1b and 2 are expected to initiate in\nSeptember or October of 2026, as follows:\"\n\nPreeclampsia (PE)\n\n\n * Part 1a late-onset PE: dose-escalation study evaluating single intravenous\n(IV) / single subcutaneous (SC) DM199 doses in late-onset PE subjects enrolled\nwithin 72 hours of delivery, including a confirmatory extension cohort of up\nto 12 participants at the cohort 10 dose level, which was completed in June\n2026.\n\n * Part 1b late-onset PE: dose-expansion study evaluating continuous IV infusion\nin up to 30 late-onset PE subjects enrolled within 72 hours of delivery, using\na dosing level identified in Part 1a; initial enrollment expected in September\nor October 2026.\n\n * Part 2 early-onset PE: evaluation of repeated SC dosing of DM199 in up to 30\nearly-onset PE subjects until delivery (expectant management), using three\ndose levels at 5, 10 and up to 15 µg/kg. The dose for the third cohort will\nbe between 1 and 15 µg/kg based on results from the first two cohorts;\ninitial enrollment expected in September or October 2026.\n\nFetal Growth Restriction (FGR)\n\n\n * Part 3 early-onset FGR: evaluating repeated SC dosing in up to 30 early-onset\nFGR subjects until delivery, using up to three dose levels initially based on\nPart 1a data; enrollment commenced in June 2026 and the first cohort of 6\nparticipants has been enrolled. Dosing levels are at 5, 10 and up to 15\nµg/kg. The dose for the third cohort will be between 1 and 15 µg/kg based on\nresults from the first two cohorts.\n\nAbout Fetal Growth Restriction\n\nFetal growth restriction (FGR) occurs when a fetus fails to reach its\ngenetically determined growth potential in the womb, most commonly due to\nplacental insufficiency. FGR affects an estimated 10% of pregnancies worldwide\nand is associated with significantly increased risks of stillbirth, preterm\nbirth, and neonatal morbidity, as well as long-term neurodevelopmental,\ncardiovascular, and metabolic complications. In severe, early-onset cases, FGR\noften necessitates delivery before 32 weeks of gestation, when the risks of\nprematurity must be weighed against the dangers of continued growth\nrestriction in utero. See the recently released white paper, “The Potential\nof DM199 to Treat Fetal Growth Restriction\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fd1io3yog0oux5.cloudfront.net%2F_de2d89f8a81650134a07cdc600a9236c%2Fdiamedica%2Fdb%2F202%2F3331%2Fpdf%2FTHE%2BPOTENTIAL%2BOF%2BDM199%2BTO%2BTREAT%2BFETAL%2BGROWTH%2BRESTRICTION.pdf&esheet=54586996&newsitemid=20260810989621&lan=en-US&anchor=The+Potential+of+DM199+to+Treat+Fetal+Growth+Restriction&index=3&md5=dbdaddeeb72ffbeebfbd06ff48056bab)\n.”\n\nAbout Preeclampsia\n\nPreeclampsia is a serious pregnancy disorder that typically develops after the\n20th week of gestation, characterized by high blood pressure and damage to\norgan systems, often the kidneys and liver. Affecting up to 8% of pregnancies\nworldwide, preeclampsia can pose significant risks to both the mother and\nbaby, including risk of stroke, placental abruption, progression to eclampsia,\npremature delivery, and death. Preeclampsia occurs in two stages. First, in\nearly pregnancy, the placenta fails to embed properly in the wall of the\nuterus, and the spiral arteries in the uterine wall that are supposed to\ndilate to promote healthy blood flow to the placenta do not widen. Stage 2\nthen occurs after 20 weeks of pregnancy as the placenta, which has been\nchronically starved of oxygen from the blood, begins to release noxious\nfactors into the mother’s circulation, inflicting widespread damage to her\nblood vessels and causing systemic endothelial dysfunction. Symptoms may\ninclude severe headaches, vision changes, upper abdominal pain and swelling in\nthe hands and face. Delivery of the baby, often very prematurely, is the only\navailable option for stopping the progression of preeclampsia. Women who have\nhad preeclampsia have three to four times the risk of high blood pressure and\ndouble the risk for heart disease and stroke.\n\nAbout Acute Ischemic Stroke\n\nAcute ischemic stroke (AIS) occurs when a blood clot blocks a vessel supplying\nblood to the brain, leading to a sudden loss of oxygen and nutrients and, if\nnot corrected, ultimately neuronal cell death. According to the U.S. Center\nfor Disease Control, stroke causes approximately one out of every 20 deaths in\nthe U.S. each year, and nearly nine out of 10 strokes are ischemic. No new\ntherapeutics have been approved for acute ischemic stroke in over 25 years.\nWhen a blood vessel in the brain becomes blocked during a stroke, a core area\nof the affected brain tissue will typically suffer a nearly complete loss of\nblood flow, while the surrounding area (the “ischemic penumbra”) receives\nonly about 20-40% of normal blood flow. Cells in the core area are rapidly\ndepleted of their oxygen and glucose stores, leading, often within minutes, to\ncell death. The cells in the penumbral area may remain viable for several\nhours but are eventually at risk of damage.\n\nAbout DiaMedica Therapeutics Inc.\n\nDiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company\ncommitted to improving the lives of people suffering from serious ischemic\ndiseases with a focus on preeclampsia, fetal growth restriction and acute\nischemic stroke. DiaMedica’s lead candidate DM199 is the first\npharmaceutically active recombinant (synthetic) form of the KLK1 protein, an\nestablished therapeutic modality in Asia for the treatment of acute ischemic\nstroke, preeclampsia and other vascular diseases. For more information visit\nthe Company’s website at www.diamedica.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.diamedica.com&esheet=54586996&newsitemid=20260810989621&lan=en-US&anchor=www.diamedica.com&index=4&md5=9b4b94de2913a03d49b3dc95ae3ac67e)\n.\n\nCautionary Note Regarding Forward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nthe U.S. Private Securities Litigation Reform Act of 1995 and forward-looking\ninformation that are based on the beliefs of management and reflect\nmanagement’s current expectations. When used in this press release, the\nwords “anticipate,” “believe,” “continue,” “could,”\n“estimate,” “expect,” “intend,” “may,” “might,”\n“plan,” “potential,” “predict,” “project,” “seek,”\n“should,” “target,” “will,” or “would,” the negative of these\nwords or such variations thereon or comparable terminology and the use of\nfuture dates are intended to identify forward-looking statements and\ninformation. The forward-looking statements and information in this press\nrelease include statements regarding the timing, nature and requirements for\nregulatory applications and approvals, including its application for an IND\nfor the study of DM199 as a treatment for preeclampsia and fetal growth\nrestriction and its conducting a Phase 2 trial in these indications; continued\nReMEDy2 trial enrollment and timing of the interim analysis; anticipated\nclinical benefits and success of DM199 for the treatment of preeclampsia,\nfetal growth restriction and acute ischemic stroke; future R&D and G&A\nexpenses and the Company’s projected cash runway. By their nature,\nforward-looking statements involve known and unknown risks, uncertainties and\nother factors which may cause actual results, performance or achievements, or\nother future events, to be materially different from any future results,\nperformance or achievements expressed or implied by such forward-looking\nstatements. Applicable risks and uncertainties include, among others, risks\nand uncertainties relating to the timing and outcomes of non-clinical studies;\nrisks and uncertainties relating to the timing of studies and trials; risks\nand uncertainties relating to the clinical expansion into preeclampsia and\nassociated trials; the risk that existing preclinical and clinical data may\nnot be predictive of the results of ongoing or later clinical trials;\nDiaMedica’s plans to develop, obtain regulatory approval for and\ncommercialize its DM199 product candidate for the treatment of preeclampsia,\nfetal growth restriction, and acute ischemic stroke and its expectations\nregarding the benefits of DM199; DiaMedica’s ability to conduct successful\nclinical testing of DM199 and within its anticipated parameters, site\nactivations, enrollment numbers, costs and timeframes; the perceived benefits\nof DM199 over existing treatment options; the potential direct or indirect\nimpact of hospital and medical facility staffing shortages, increased tariffs\nand worldwide global supply chain shortages on DiaMedica’s business and\nclinical trials, including its ability to meet its site activation and\nenrollment goals; DiaMedica’s reliance on collaboration with third parties\nto conduct clinical trials; DiaMedica’s ability to continue to obtain\nfunding for its operations, including funding necessary to complete current\nand planned clinical trials and obtain regulatory approvals for DM199 for\npreeclampsia, fetal growth restriction, and acute ischemic stroke; and the\nrisks identified under the heading “Risk Factors” in DiaMedica’s annual\nreport on Form 10-K for the fiscal year ended December 31, 2025 filed with the\nU.S. Securities and Exchange Commission (SEC) and subsequent SEC reports,\nincluding our most recent quarterly report on Form 10-Q. The forward-looking\ninformation contained in this press release represents the expectations of\nDiaMedica as of the date of this press release and, accordingly, is subject to\nchange after such date. Readers should not place undue importance on\nforward-looking information and should not rely upon this information as of\nany other date. While DiaMedica may elect to, it does not undertake to update\nthis information at any particular time except as required in accordance with\napplicable laws.\n   \n   \n   \n DiaMedica Therapeutics Inc. \n \nCondensed Consolidated Statements of Operations and Comprehensive Loss \n \n(In thousands, except share and per share amounts) \n \n(Unaudited)  \n   \n   Three Months Ended June 30,     Six Months Ended June 30,   \n   2026     2025     2026     2025   \n Operating expenses:                               \n Research and development $ 8,153     $ 5,822     $ 16,140     $ 11,478   \n General and administrative   2,345       2,185       4,840       4,673   \n Operating loss   (10,498 )     (8,007 )     (20,980 )     (16,151 ) \n                                 \n Other income, net   366       314       813       757   \n                                 \n Loss before income tax expense   (10,132 )     (7,693 )     (20,167 )     (15,394 ) \n                                 \n Income tax expense   (7 )     (6 )     (14 )     (12 ) \n                                 \n Net loss   (10,139 )     (7,699 )     (20,181 )     (15,406 ) \n                                 \n Other comprehensive loss                               \n Unrealized loss on marketable securities   (11 )     (19 )     (87 )     (37 ) \n                                 \n Net loss and comprehensive loss $ (10,150 )   $ (7,718 )   $ (20,268 )   $ (15,443 ) \n                                 \n Basic and diluted net loss per share $ (0.19 )   $ (0.18 )   $ (0.38 )   $ (0.36 ) \n Weighted average shares outstanding – basic and diluted   53,894,295       42,957,619       53,844,171       42,901,093   \n\n   \n   \n   \n   \n DiaMedica Therapeutics Inc. \n \nCondensed Consolidated Balance Sheets \n \n(In thousands, except share amounts)  \n   \n     June 30, 2026     December 31, 2025   \n     (unaudited)           \n ASSETS                 \n Current assets:                 \n Cash and cash equivalents   $ 5,129     $ 15,647   \n Marketable securities     38,375       44,243   \n Prepaid expenses and other assets     567       481   \n Amounts receivable     244       258   \n Total current assets     44,315       60,629   \n                   \n Non-current assets:                 \n Operating lease right-of-use asset, net     400       400   \n Property and equipment, net     153       197   \n Deposits     133       145   \n Total non-current assets     686       742   \n                   \n Total assets   $ 45,001     $ 61,371   \n                   \n LIABILITIES AND EQUITY                 \n Current liabilities:                 \n Accounts payable   $ 2,812     $ 1,475   \n Accrued liabilities     3,666       3,545   \n Operating lease obligation     107       101   \n Finance lease obligation     9       11   \n Total current liabilities     6,594       5,132   \n                   \n Non-current liabilities:                 \n Operating lease obligation     69       124   \n Finance lease obligation     —       4   \n Total non-current liabilities     69       128   \n                   \n Shareholders’ equity:                 \n Common shares, no par value; unlimited authorized; 53,925,697 and 42,818,660     —       —   \n shares issued and outstanding, as of June 30, 2026 and December 31, 2025, \n respectively \n Paid-in capital     231,324       228,829   \n Accumulated other comprehensive income (loss)     (37 )     50   \n Accumulated deficit     (192,949 )     (172,768 ) \n Total shareholders’ equity     38,338       56,111   \n Total liabilities and shareholders’ equity   $ 45,001     $ 61,371   \n\n   \n   \n   \n   \n DiaMedica Therapeutics Inc. \n \nCondensed Consolidated Statements of Cash Flows \n \n(In thousands) \n \n(Unaudited)  \n   \n     Six Months Ended June 30,   \n     2026     2025   \n Cash flows from operating activities:                 \n Net loss   $ (20,181 )   $ (15,406 ) \n Adjustments to reconcile net loss to net cash used in operating activities:             \n Share-based compensation     1,940       1,638 \n Amortization of discounts on marketable securities     (359 )     (441 ) \n Non-cash lease expense     44       40   \n Depreciation     23       14   \n Changes in operating assets and liabilities:               \n Amounts receivable     14       75 \n Prepaid expenses and other assets     (86 )     (453 ) \n Deposits     —       1,108   \n Accounts payable     1,337       321   \n Accrued liabilities and operating lease liabilities     72       (1,643 ) \n Net cash used in operating activities     (17,196 )     (14,747 ) \n               \n Cash flows from investing activities:               \n Purchase of marketable securities     (23,650 )     (16,370 ) \n Maturities and sales of marketable securities     29,790       31,967 \n Purchases of property and equipment     (11 )     (18 ) \n Net cash provided by investing activities     6,129       15,579 \n               \n Cash flows from financing activities:               \n Proceed from the exercise of common stock options     555       257   \n Principal payments on finance lease obligation     (6 )     (5 ) \n Net cash provided by financing activities     549       252 \n             \n Net increase (decrease) in cash and cash equivalents     (10,518 )     1,084 \n Cash and cash equivalents at beginning of period     15,647       3,025 \n Cash and cash equivalents at end of period   $ 5,129     $ 4,109 \n                 \n Supplemental disclosure of non-cash transactions:                 \n Cash paid for income taxes   $ 13     $ 12 \n   \n   \n\n\n \n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260810989621/en/\n(https://www.businesswire.com/news/home/20260810989621/en/)\n\nScott Kellen\n\nChief Financial Officer\n\nPhone: (763) 496-5118\n\nskellen@diamedica.com (mailto:skellen@diamedica.com)\n\nFor Investor Inquiries: \n\nMike Moyer\n\nManaging Director, LifeSci Advisors, LLC\n\nPhone: (617) 308-4306\n\nmmoyer@lifesciadvisors.com (mailto:mmoyer@lifesciadvisors.com)\n\nMedia Contact: \n\nMadelin Hawtin\n\nLifeSci Communications\n\nmhawtin@lifescicomms.com \n(mailto:mhawtin@lifescicomms.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-08-10T20:30:00.641724302Z","server_sent_at_ms":1786393800641},"received_at":"2026-08-10T20:30:01.056Z","source_url":"https://www.businesswire.com/news/home/20260810989621/en/"},"analysis":{"id":"103638","press_release_id":"114638","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["FDA indicated that an additional rat pharmacokinetic and pharmacologic activity study is required to support IND clearance for preeclampsia","Cash position decreased by $16.4 million in six months"],"eventType":"earnings","narrative":"DiaMedica reported Q2 financial results with $43.5 million in cash and investments, providing a runway to fund operations through 2027, while recording a net loss of $10.1 million for the quarter.\n\nThe company announced positive topline results from the Phase 2 late-onset preeclampsia study, showing a statistically significant mean reduction of 29.1 mmHg in systolic blood pressure.\n\nClinical progress continues across the pipeline, with enrollment in the acute ischemic stroke ReMEDy2 trial surpassing 85% and the first cohort of the fetal growth restriction trial completing enrollment.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Positive Phase 2 data in preeclampsia validates mechanism as cash runway extends into 2027."},"keyFigures":{"customDimensions":{"runway":"through 2027","net_loss_q2":10100000,"cash_position":43500000,"dbp_reduction":"17.0 mmHg","sbp_reduction":"29.1 mmHg","rd_expenses_6m":16100000,"rd_expenses_q2":8200000,"working_capital":37700000,"net_cash_used_in_ops":17200000}},"quotedText":"With the recent positive interim results from Part 1a of our Phase 2 study evaluating DM199 in preeclampsia, we’re eager to continue advancement of this promising candidate to address ischemic diseases in the second half of this year","namedEntities":{"people":[{"name":"Rick Pauls","role":"President and CEO"},{"name":"Julie Krop","role":"Chief Medical Officer"},{"name":"Cathy Cluver","role":"Principal Investigator"},{"name":"Scott Kellen","role":"Chief Financial Officer"}],"products":["DM199"],"companies":[{"name":"DiaMedica Therapeutics Inc.","ticker":"DMAC"},{"name":"Health Canada","relationship":"regulator"},{"name":"U.S. Food and Drug Administration","relationship":"regulator"},{"name":"LifeSci Advisors, LLC","relationship":"Investor Relations"},{"name":"LifeSci Communications","relationship":"Media Contact"}],"dollarAmounts":[{"amount":"$43.5 million","context":"Cash, cash equivalents and short-term investments"},{"amount":"$59.9 million","context":"Cash position as of December 31, 2025"},{"amount":"$37.7 million","context":"Working capital"},{"amount":"$17.2 million","context":"Net cash used in operating activities for the six months ended June 30, 2026"},{"amount":"$8.2 million","context":"R&D expenses for the three months ended June 30, 2026"},{"amount":"$10.1 million","context":"Net loss for the three months ended June 30, 2026"}]},"materialImpact":{"score":3,"reasoning":"Positive Phase 2 topline data in preeclampsia demonstrated statistically significant blood pressure reductions, validating the drug's mechanism. While not a binary regulatory event, the data de-risks the program and supports Phase 3 planning. The company maintains sufficient cash runway through 2027."},"tickerRelevance":{"others":[],"primary":"DMAC"},"globalImportance":25,"audienceRelevance":15,"eventTypeSecondary":["clinical_trial"],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"positive_phase_2_data","sectorWeight":"biotech"}},"event_type":"earnings","event_type_secondary":["clinical_trial"],"sentiment":"bullish","material_impact_score":3,"narrative":"DiaMedica reported Q2 financial results with $43.5 million in cash and investments, providing a runway to fund operations through 2027, while recording a net loss of $10.1 million for the quarter.\n\nThe company announced positive topline results from the Phase 2 late-onset preeclampsia study, showing a statistically significant mean reduction of 29.1 mmHg in systolic blood pressure.\n\nClinical progress continues across the pipeline, with enrollment in the acute ischemic stroke ReMEDy2 trial surpassing 85% and the first cohort of the fetal growth restriction trial completing enrollment.","key_figures":{"customDimensions":{"runway":"through 2027","net_loss_q2":10100000,"cash_position":43500000,"dbp_reduction":"17.0 mmHg","sbp_reduction":"29.1 mmHg","rd_expenses_6m":16100000,"rd_expenses_q2":8200000,"working_capital":37700000,"net_cash_used_in_ops":17200000}},"named_entities":{"people":[{"name":"Rick Pauls","role":"President and CEO"},{"name":"Julie Krop","role":"Chief Medical Officer"},{"name":"Cathy Cluver","role":"Principal Investigator"},{"name":"Scott Kellen","role":"Chief Financial Officer"}],"products":["DM199"],"companies":[{"name":"DiaMedica Therapeutics Inc.","ticker":"DMAC"},{"name":"Health Canada","relationship":"regulator"},{"name":"U.S. Food and Drug Administration","relationship":"regulator"},{"name":"LifeSci Advisors, LLC","relationship":"Investor Relations"},{"name":"LifeSci Communications","relationship":"Media Contact"}],"dollarAmounts":[{"amount":"$43.5 million","context":"Cash, cash equivalents and short-term investments"},{"amount":"$59.9 million","context":"Cash position as of December 31, 2025"},{"amount":"$37.7 million","context":"Working capital"},{"amount":"$17.2 million","context":"Net cash used in operating activities for the six months ended June 30, 2026"},{"amount":"$8.2 million","context":"R&D expenses for the three months ended June 30, 2026"},{"amount":"$10.1 million","context":"Net loss for the three months ended June 30, 2026"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-11T00:40:29.668Z","global_importance":25,"audience_relevance":15,"importance_components":{"tickerTier":"micro-cap","eventGravity":"positive_phase_2_data","sectorWeight":"biotech"}},"durationMs":255606,"modelName":"glm-4.7"}}